Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Blood

Volumn 122, Issue 16, 2013, Pages 2807-2811

  Takahashi, Koichi ^a,b   Pemmaraju, Naveen ^a   Strati, Paolo ^a   Nogueras Gonzalez, Graciela ^a   Ning, Jing ^a   Bueso Ramos, Carlos ^a   Luthra, Rajyalakshmi ^a   Pierce, Sherry ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; AZACITIDINE; CYTARABINE; ETOPOSIDE; GYRASE INHIBITOR; HYDROXYUREA; IDARUBICIN; LENALIDOMIDE; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DRUG EXPOSURE; ERYTHROCYTE TRANSFUSION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION RESPONSE; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

EID: 84888259429     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491399     Document Type: Article

References (14)

1. Swerdlow SH, International Agency for Research on Cancer. World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008
2. Bennett JM, Catovsky D, Daniel MT, et al; Proposals by the French-American-British Cooperative Leukaemia Group. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol. 1994;87(4):746-754.
3. Ahmed F, Osman N, Lucas F, et al. Therapy related CMML: a case report and review of the literature. Int J Hematol. 2009;89(5):699-703.
4. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica. 2005;90(5):691-693.
5. Ueki K, Sato S, Tamura J, et al. Three cases of multiple myeloma developing into melphalanrelated chronic myelomonocytic leukemia. J Med. 1991;22(3):157-161.
6. Oo TH, Kenney L. Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: monosomy 7 and t (12;17) (p13;q11.2). Am J Hematol. 2007;82(3):248-249.
7. Kim KB, Faderl S, Hwang CS, Khuri FR. Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. J Clin Pharm Ther. 2006;31(4):401-406.
8. Zuo Z, Chen SS, Chandra PK, et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009;22(8):1023-1031.
9. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013;37(5):552-555.
10. Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752-756.
11. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005-3015.
12. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375-383.
13. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840-849.
14. Nardi V, Winkfield KM, Ok CY, et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapyrelated myeloid neoplasms. J Clin Oncol. 2012;30(19):2340-2347.